US Patent

US10548889 — Compositions of CXCR4 inhibitors and methods of preparation and use

Formulation · Assigned to X4 Pharmaceuticals Inc · Expires 2038-12-11 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods of use for treating, preventing, or ameliorating diseases associated with the CXCR4 chemokine receptor.

USPTO Abstract

The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.

Drugs covered by this patent

Patent Metadata

Patent number
US10548889
Jurisdiction
US
Classification
Formulation
Expires
2038-12-11
Drug substance claim
No
Drug product claim
Yes
Assignee
X4 Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.